BioMarin Pharmaceutical's Achondroplasia Treatment Gets FDA Approval for All Pediatric Patients
By Sabela Ojea
BioMarin Pharmaceutical said the Food and Drug Administration has approved its new drug application to treat all pediatric patients with a growth condition.
The biotechnology company on Friday said its Voxzogo treatment is aimed at increasing linear growth and has been approved based on an improvement in annualized growth velocity.
The medication had previously been indicated for achondroplasia patients who were 5 years of age and older.
Voxzogo is currently approved in Europe for children with achondroplasi who are at least 2 years old.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
October 20, 2023 16:39 ET (20:39 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks